Processing

Please wait...

Settings

Settings

1. WO2013079493 - AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS

Publication Number WO/2013/079493
Publication Date 06.06.2013
International Application No. PCT/EP2012/073761
International Filing Date 28.11.2012
Chapter 2 Demand Filed 16.08.2013
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02
not condensed with other rings
24
having three or more double bonds between ring members or between ring members and non-ring members
28
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
32
One oxygen, sulfur or nitrogen atom
42
One nitrogen atom
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02
not condensed with other rings
24
having three or more double bonds between ring members or between ring members and non-ring members
28
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
46
Two or more oxygen, sulfur or nitrogen atoms
48
Two nitrogen atoms
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
C07D 239/42 (2006.01)
C07D 239/48 (2006.01)
A61K 31/505 (2006.01)
CPC
C07D 239/42
C07D 239/48
C07D 401/04
C07D 401/12
C07D 403/04
C07D 403/12
Applicants
  • F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124 CH-4070 Basel, CH (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
  • BAKER-GLENN, Charles [GB/GB]; GB (US)
  • CHAMBERS, Mark [GB/GB]; GB (US)
  • CHAN, Bryan K. [CA/US]; US (US)
  • CHEN, Huifen [US/US]; US (US)
  • ESTRADA, Anthony [US/US]; US (US)
  • SHORE, Daniel [US/US]; US (US)
  • SWEENEY, Zachary [US/US]; US (US)
Inventors
  • BAKER-GLENN, Charles; GB
  • CHAMBERS, Mark; GB
  • CHAN, Bryan K.; US
  • CHEN, Huifen; US
  • ESTRADA, Anthony; US
  • SHORE, Daniel; US
  • SWEENEY, Zachary; US
Agents
  • MUELLER-AFRAZ, Simona; Grenzacherstrasse 124 CH-4070 Basel, CH
Priority Data
61/564,75329.11.2011US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS
(FR) DÉRIVÉS AMINOPYRIDINES EN TANT QUE MODULATEURS DE LRRK2
Abstract
(EN)
Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
(FR)
L'invention concerne des composés de formule (I) : Formule (I) ou des sels pharmaceutiquement acceptables de ceux-ci, où m, n, X, R1, R2, R3, R4 et R5 sont tels que défini présentement. L'invention concerne également des procédés de fabrication des composés et d'utilisation des composés pour le traitement de maladies associées à un récepteur de LRRK2, telle que la maladie de Parkinson.
Latest bibliographic data on file with the International Bureau